Characteristics | Group A | Group B |
---|---|---|
No. of patients | 18 | 19 |
Age at diagnosis, y | ||
Median | 3.3 | 1.0 |
Range | 0.5—11.1 | 0.6—3.6 |
Gender | ||
Male | 11(61.1%) | 10(52.6%) |
Female | 7(38.9%) | 9(47.4%) |
Follow-up, m | ||
Median | 38.08 | 38.93 |
Range | 21.34—43.73 | 22.52—71.47 |
Inflammatory symptoms (no. of patients) | ||
Rash | 1(5.6%) | 17(89.5%) |
Ear canal lesions | 1(5.6%) | 8(42.2%) |
Bone damage | 18(100%) | 7(36.8%) |
Gastrointestinal symptoms | 1(5.6%) | 5(26.3%) |
Pulmonary symptoms | 0 | 12(63.2%) |
Liver symptoms | 1(5.6%) | 17(89.5%) |
Endocrine system symptoms | 0 | 1(5.3%) |
Central nervous system symptoms | 1(5.6%) | 3(15.8%) |
Malignant symptoms (no. of patients) | ||
Fever | 0 | 19(100%) |
Gingival or palatal swelling | 0 | 1(5.3%) |
Splenomegaly | 0 | 16(84.2%) |
Mass of body or organ | 0 | 2(10.5%) |
Lymphadenopathy | 0 | 4(21.1%) |
Hematologic symptoms | 0 | 19(100%) |